COMPASS Pathways plc 1Q 2026: Revenue $91.2M, EPS ($0.3) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
COMPASS Pathways plc reported a significant revenue increase to $91.2M in Q1 2026, compared to a loss of $17.98M in the same quarter last year. The diluted EPS was ($0.3), an improvement from ($0.24) year-over-year. Key highlights include completion of Phase 3 trials, FDA's rolling review for COMP360, and initiation of a Phase 2b/3 PTSD trial. The company is also preparing for a potential commercial launch, contingent on final Phase 3 data.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments